Public Funding for Sentinel Oncology Limited

no public description

Glioblastoma multiforme (GBM) is one of the most common forms of brain cancer and is currently very poorly treated. Most patients have an average survival of less than 15 months and the five-year survival prognosis is less than 5%. The most recent new drug approved for the treatment of GBM was temozolomide, approved in 2005. There is a clear unmet need for new drugs to treat GBM and Sentinel Oncology will develop a new drug called SOL288 as the main objective of this project.

There are no effective treatments for Alzheimer’s disease. The incidence and health care costs of treating dementia are set to increase in the coming decades and there is an overwhelming need for effective treatments. Sentinel Oncology Limited (SOL) has developed a new class of drug molecules that have the potential to treat Alzheimer’s Disease. These new drugs would work by preventing the production and activation of proteins in the brain that are involved with the progression of the disease. The purpose of this project is to carry out proof-of-concept experiments to confirm if the SOL drugs have the potential to treat patients with Alzheimer’s Disease.

FXSFIX will deliver a diagnostic biomarker for use with SOL101, a clinical candidate drug for the treatment of Fragile X Syndrome (FXS). SOL101 is a first in class drug for FXS which is an orphan disease with no current clinically available treatments. SOL101 is an inhibitor of p70 S6 kinase 1 (S6K1), a protein recently shown to have utility in the control of aberrant protein production which is a phenotypic hallmark of FXS and will aim to reverse the symptoms suffered by patients.

Fragile X Syndrome is the single largest cause of genetically inherited disability amongst diseases categorised within the autism spectrum disorders. This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which will treat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstrated proof of concept in pre-clinical disease models and the proposal will develop it to the start of clinical trials. As well as the healthcare benefits to the patiens, in terms of alleviation of symptoms, both neurological and physical, the cost savings in terms of reduced needs for ongoing care and education assistance will be considerable. Finance summary table

There is a continuing need for new and more effective medicines to treat cancer patients. Despite a steady increase in the number of clinical treatment options available to patients, the number of people being diagnosed with cancer is growing. Sentinel Oncology is a company dedicated to the design and development of new and innovative approaches for the treatment of cancer. The objective of this project is to identify a new drug suitable for the treatment of pancreatic cancer, a disease with very few, if any suitable treatments currently available and for which the prognosis for patients is extemely poor. The successful completion of this project will allow clinicians to develop clinical trials which will be designed to safely enhance the anti-cancer effects of current standards of care for pancreatic cancer.

There is a continuing need for new and more effective medicines to treat cancer patients. Despite a steady increase in the number of clinical treatment options available to patients, the number of people being diagnosed with cancer is growing with each passing year and resistence to current therapies is becoming a concerning issue to clinicians. Sentinel Oncology is a company dedicated to the design and development of new and innovative approaches for the treatment of cancer. The objective of this project is study a promising new experimental drug in a variety of difficult to cure cancers including resistant breast cancer, oesophageal cancer, ovarian cancer and leukaemia. The outcome of the project will help define the clinical experiments required to ultimately assess this approach in cancer patients.

Glioblastoma is a cancer of the brain which, although relatively rare, has a very poor survival rate. It is particularly deadly in young patients and overall survival for all patient groups over 5 years is less than 3%. One reason for the poor prognosis and survival rate is that the available treatments have progressed very little over the past 30 years, with surgery followed by radiotherapy being the only real option. Glioblastoma tumours rapidly develop resistance to treatment and the aim of this project will be to develop a drug with the ability to reverse that resistance and make the existing therapies effective once more.

Awaiting Public Project Summary